SANXING(SH:601567) Huaxin Securities·2025-10-19 11:33Investment Rating - The report assigns a "Buy" rating for the company, Samsung Medical (601567.SH) [1][8] Core Insights - The company has experienced significant growth in overseas orders, with a 51% year-on-year increase in overseas revenue, reaching 1.495 billion yuan [4] - The company is expanding its production capacity to alleviate bottlenecks in its distribution business, with a new project expected to produce 16,000 sets of new energy box substations annually [4] - The company maintains a leading position in domestic power grid business and has made breakthroughs in non-grid business sectors, particularly in renewable energy [5][7] Summary by Sections Market Performance - The stock price is currently at 24 yuan, with a market capitalization of 33.7 billion yuan and a 52-week price range of 21.21 to 34.48 yuan [1] Financial Performance - In the first half of the year, the company achieved operating revenue of 7.97 billion yuan, a 14% increase year-on-year, and a net profit of 1.23 billion yuan, up 7% [3] - The gross margin for the first half was 28.97%, down 5.64 percentage points year-on-year, while the net margin was 15.43%, down 1 percentage point [3] Order Backlog and Growth - The total order backlog reached 17.632 billion yuan, an 18.39% increase year-on-year, with overseas distribution orders growing by 123.96% to 2.182 billion yuan [4] - The company is focusing on high-end markets in Europe, the Middle East, and Latin America, with successful bids in Hungary, Romania, and Kyrgyzstan [4] Profit Forecast - Revenue projections for 2025-2027 are 16.1 billion, 18.9 billion, and 22.4 billion yuan, respectively, with corresponding EPS of 1.76, 2.14, and 2.62 yuan [8][10]